Biotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
BioNTech SE
BNTX
Current price
$111.40
As a key player in the lawsuit, BioNTech's situation highlights the immense value and risk associated with its foundational mRNA intellectual property...
As a key player in the lawsuit, BioNTech's situation highlights the immense value and risk associated with its foundational mRNA intellectual property.
CRISPR Therapeutics AG
CRSP
Current price
$54.16
As a leader in CRISPR gene-editing, the company's foundational intellectual property represents a significant competitive moat in the therapeutic spac...
As a leader in CRISPR gene-editing, the company's foundational intellectual property represents a significant competitive moat in the therapeutic space.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Patents are the crown jewels of biotech companies. Recent high-profile disputes between Pfizer, BioNTech, and Moderna highlight how valuable intellectual property is in this sector. Companies with strong patents can protect their innovations, command premium pricing, and generate licensing revenue for years.
What You Need to Know
This collection focuses on companies with "IP moats" - strong patent portfolios that protect their innovations from competitors. These stocks typically represent higher-risk, higher-reward investments in cutting-edge fields like gene editing, cell therapy, and RNA-based medicine, where breakthroughs can lead to substantial returns.
Why These Stocks
These companies were selected because they either have established intellectual property in revolutionary technologies or are developing the next generation of patentable breakthroughs. Their business models often depend on securing and defending foundational patents that can provide sustainable advantages in highly competitive markets.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+381.08%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 381.08% over the next year.
Stocks Rated Buy by Analysts
13 of 15 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 88.3% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
The Patent Power Play
The Pfizer-Moderna lawsuit has put a spotlight on how valuable intellectual property can be in biotech. Companies that win these battles can secure billions in licensing fees or damages, creating massive shareholder value overnight.
Tomorrow's Breakthroughs Today
These companies aren't just developing treatments, they're creating entirely new ways to fight disease. Their groundbreaking platforms in gene editing and cell therapy could revolutionize medicine and generate huge returns for early investors.
Built-in Competitive Protection
Strong patents act like a moat around a castle, keeping competitors at bay for years or even decades. This protection allows these companies to maintain premium pricing and higher profit margins than other sectors.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.